Neurogene
Mr. Jimenez has spent more than 20 years in the pharmaceutical and biotechnology industry, with 16 of those years in the gene therapy field. Prior to Neurogene, Mr. Jimenez was the site head of the Lonza Houston manufacturing facility and played a leadership role in establishing Lonza as a major contract cellular and gene therapy manufacturer, including designing and overseeing the construction of the cell and gene therapy facility in Texas. He started in gene therapy in 2005 at Introgen Therapeutics, where he was responsible for the validation activities for adenoviral-based products and served as Head of Quality in what became in 2009 Vivante GMP Solutions, a contract manufacturing organization acquired by Lonza. Mr. Jimenez holds a B.S. in biomedical science from Texas A&M University.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.